[1] |
RAJA K R,KOVAROVA L,HAJEK R.Review of phenotypic markers used in flow cytometric analysis of MGUS and MM,and applicability of flow cytometry in other plasma cell disorders[J]. Br J Haematol,2010,149(3):334-351.
|
[2] |
郭娟,常春康,苏基滢,等. 应用流式细胞术评估多发性骨髓瘤预后的研究进展[J]. 中国实验血液学杂志,2014,22(4):1178-1182.
|
[3] |
RAWSTRON A C,GREGORY W M,DE TUTE R M,et al. Minimal residual disease in myeloma by flow cytometry:independent prediction of survival benefit per log reduction[J]. Blood,2015,125(12):1932-1935.
|
[4] |
RAWSTRON A C,ORFAO A,BEKSAC M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3):431-438.
|
[5] |
FRIGYESI I,ADOLFSSON J,ALI M,et al.Robust isolation of malignant plasma cells in multiple myeloma[J]. Blood,2014,123(9):1336-1340.
|
[6] |
CUENCA M,ROMERO X,SINTES J,et al.Targeting of Ly9(CD229)disrupts marginal zone and B1 B cell homeostasis and antibody responses[J]. J Immunol,2016,196(2):726-737.
|
[7] |
CARULLI G,BUDA G,AZZARÀ A,et al.CD229 expression on bone marrow plasma cells from patients with multiple myeloma and monoclonal gammopathies of uncertain significance[J]. Acta Haematol,2016,135(1):11-14.
|
[8] |
RAWSTRON A C,ORFAO A,BEKSAC M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders[J]. Haematologica,2008,93(3):431-438.
|
[9] |
KAWANO Y,KIKUKAWA Y,FUJIWARA S,et al.Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells[J]. Int J Oncol,2013,43(6):1809-1816.
|
[10] |
GRIGORIADIS G,WHITEHEAD S.CD138 shedding in plasma cell myeloma[J]. Br J Haematol,2010,150(3):249.
|
[11] |
LIN P,OWENS R,TRICOT G,et al.Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma[J]. Am J Clin Pathol,2004,121(4):482-488.
|
[12] |
KHAGI Y,MARK T M.Potential role of daratumumab in the treatment of multiple myeloma[J]. Onco Targets Ther,2014,7:1095-1100.
|
[13] |
LAUBACH J P,TAI Y T,RICHARDSON P G,et al.Daratumumab granted breakthrough drug status[J]. Expert Opin Investig Drugs,2014,23(4):445-452.
|
[14] |
VASUTHASAWAT A,YOO E M,TRINH K R,et al.Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma[J]. MAbs,2016,8(7):1386-1397.
|